NICE Issues Two Major 2025 Approvals: Vutrisiran for ATTR-CM and Aucatzyl CAR-T for R/R B-ALL
NICE has issued two major decisions: recommending vutrisiran for adult ATTR-CM and approving Aucatzyl CAR-T for relapsed or refractory B-ALL in adults.
Speciality
CMS Sets New Medicare 2026 Rates Across Five Innovation Categories
What the New Medicare 2026 Rates Mean for Access and Adoption The U.S. Centers for Medicare & Medicaid Services (CMS) has delivered a rare cluster of reimbursement decisions that collectively mark one of the most significant access-defining weeks of 2025. Spanning neuromodulation, molecular diagnostics, AI imaging, autoimmune disease therapy, and oncology support care, the rulings … Read more
NICE Issues New Updates on AI Cancer Detection, Sepsis Care, and Breast Cancer Drug Appraisal
NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
NeuroPulse Daily – ASPN PNS Guideline Headlines a Busy Day of Deals, Diagnostics, and Neurotechnology Progress
Synopulse’s NeuroPulse Daily tracks major movements across neurology, including new Parkinson’s diagnostics, ALS care funding, Huntington’s genetic medicine progress, AI-powered imaging clearance, breakthrough neurotechnology, and multimillion-dollar collaborations accelerating CNS drug discovery.
Valo Health, Merck KGaA Launch $3B+ AI Collaboration Targeting Parkinson’s Disease
Valo Health has entered a collaboration with Merck KGaA, Darmstadt, Germany worth over $3 billion to accelerate AI-driven discovery of Parkinson’s disease therapies.
B. Braun to Pay $38.5M in DOJ Settlement Over Allegedly Faulty Knee Implant and False Claims
The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
Alkermes Raises Avadel Acquisition Offer to $2.37B, Outmaneuvering Lundbeck With Superior CVR Terms
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
NeuroPulse Daily – Key Clinical, Discovery & Device Updates Across the Field
Today’s neurology roundup highlights momentum across Alzheimer’s and ALS drug development, spinal cord injury research, intravascular imaging, and next-gen MRI technologies.
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.